Navigation Links
Data Available From Erbitux Phase III Study in First-Line Treatment,of Advanced Lung Cancer

Although the company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions it can give no assurance that its expectations will be achieved. Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the company's ability to control or predict. Important factors that may cause actual results to differ materially and could impact the company and the statements contained in this news release can be found in the company's filings with the Securities and Exchange Commission, including quarterly reports on Form 10-Q, current reports on Form 8-K and annual reports on Form 10-K. For forward-looking statements in this news release, the company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

About Bristol-Myers Squibb

Bristol-Myers Squibb is dedicated to the discovery, development and exhaustive exploration of innovative cancer fighting therapies designed to extend and enhance the lives of patients living with cancer. More than 40 years ago, Bristol-Myers Squibb built a unified vision for the future of cancer treatment. With expertise, dedication and resolve, that vision led to the development of a diverse global portfolio of anti-cancer therapies that are an important cornerstone of care today. Hundreds of scientists at Bristol- Myers Squibb's Pharmaceutical Research Institute are studying ways to improve current cancer treatments and identify better, more effective medicines for the future.

Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Positive Results Prompt US National Cancer Institute to Make Glivec Available to Patients in Post-Surgical GIST Study
2. Positive Results Prompt US National Cancer Institute to Make Gleevec Available To Patients in Post-Surgical Gist Study
3. Data Available from Erbitux Phase III Study in First-Line Treatment of Advanced Pancreatic Cancer
4. Survival Data Available From Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer
5. Survival Data Available from Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer
6. Extensive Clinical Data on Erbitux Presented at the 2007 ASCO Annual Meeting
7. Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of Erbitux for Colorectal and Head and Neck Cancer Patients
8. Randomized Phase III Trial Showed Erbitux Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients
9. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:7/10/2014)... Calif. , July 10, 2014 Integrated ... leader in advanced memory and analog IC solutions, today ... on Thursday, July 24, 2014, at 7:00 a.m. Pacific ... financial results for the fiscal 2014 third quarter ended ... call via telephone, dial 1-888-556-4997 before 6:50 a.m. Pacific ...
(Date:7/10/2014)... , July 10, 2014  BC Technical, the largest ... MiE America , Inc., a leading provider of Siemens ... a long-term agreement naming BC Technical as the authorized ... MiE and BC Technical announced today that ... establish BC Technical as the service and systems provider ...
(Date:7/10/2014)... 10, 2014  Decision Resources Group finds that ... (ID) specialists are willing to prescribe Durata,s Dalvance ... use as OPAT, approximately two-thirds of the respondents ... their hospital inpatients. However, our findings indicate that ... initiated on OPAT following hospital discharge, and most ...
Breaking Medicine Technology:BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
... for Vidaza versus 26.2 for ... patients on Vidaza compared to ... compared to conventional ... Only epigenetic modifier to show survival benefit in cancer Stratified log-rank p-value = ...
... trial of AKIi-5 as the first human clinical study ... involving the systemic ... Quark Pharmaceuticals, Inc., a,clinical-stage biopharmaceutical company focused on discovering ... positive results from preclinical efficacy studies for its,proprietary systemically-administered, ...
Cached Medicine Technology:Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS) 2Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS) 3Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS) 4Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS) 5Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS) 6Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS) 7Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS) 8Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF) 2Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF) 3Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF) 4
(Date:7/11/2014)... Cancer researchers in Slovenia say genetic ... on how patients respond to treatment with pemetrexed (Alimta), ... has the full story. Click here to read ... University of Ljubljana and the Ljubljana Institute of Oncology ... types of polymorphisms. They found that patients with genetic ...
(Date:7/11/2014)... 11, 2014 Anterior Cruciate Ligament (ACL) ... the type of material used to create a new ... game, say researchers presenting their work today at the ... Medicine ( AOSSM ). , “Our study ... (tissue harvested from a donor) fail more frequently than ...
(Date:7/11/2014)... Woodland Hills permanent teeth in one day ... Art Institute in Woodland Hills and Oxnard, Calif., will speak ... Del Rey, Calif. , The award-winning prosthodontist, international speaker ... teeth in one day dental procedure at 1:30 p.m. Friday, ... developed 15 years ago, Dr. Jivraj said. Getting new teeth ...
(Date:7/11/2014)... 2014 BellasDress, the experienced dressmaker in ... online suppliers when it comes to beach wedding ... collection of beach wedding outfits in its online shop. ... elegant outfits. , BellasDress has been considered as ... According to the company’s senior spokesman, BellasDress provides superb ...
(Date:7/11/2014)... The International Concussion Organization is hosting its 1st ... in Times Square, New York on July 17th ... that is plaguing athletes in nearly all sports ... Symposium gathers more than a dozen internationally prominent ... legal scholars for engaging and uniquely relevant scientific ...
Breaking Medicine News(10 mins):Health News:New Research Finds Genetic Variables Impact Chemotherapy Response, According to Surviving Mesothelioma 2Health News:ACL Reconstructions May Last Longer With Autografts 2Health News:Woodland Hills Dental Expert Speaking at Nobel Biocare World Symposium in One Week 2Health News:Woodland Hills Dental Expert Speaking at Nobel Biocare World Symposium in One Week 3Health News:Woodland Hills Dental Expert Speaking at Nobel Biocare World Symposium in One Week 4Health News:Woodland Hills Dental Expert Speaking at Nobel Biocare World Symposium in One Week 5Health News:BellasDress Emerges As Popular Online Supplier Of 2014 Beach Wedding Dresses 2Health News:The International Concussion Organization 501(c)(3) hosts its 1st Annual Concussion Symposium at the Best Buy Theater in Time Square, NYC, July 17th, 2014. 2
... Ala., May 27 Leading fitness social network and tracking ... name to DailyBurn , effective immediately.In just ... community of more than 125,000 members, who have, depending on ... gained an average of 5.75 lbs of muscle using DailyBurn,s ...
... Integrated Delivery Systems, Telehealth Pioneer ATI is Transforming Care for High-Risk, ... Care 24/7/365 , ... Irvine, Calif., and Minneapolis, Minn. ... now, Entrepreneur magazine named American TeleCare, Inc. (ATI) as one of ...
... HabitsMORRISTOWN, N.J., May 27 Whether it,s "powdering your nose" ... significant amount of time in the bathroom. According to ... minutes each day in the bathroom -- that adds up ... than double that of the average vacation trip(1). And ...
... ignite09 to Improve Health Outcomes and Lower CostsWASHINGTON, ... Consumerism, the American Benefits Council and Hewitt Associates ... are bringing together leaders in innovation from across ... the convergence of behavioral economics and healthcare. ...
... Longer term follow-up indicates modest efficacy in primary ... 27 Ceregene, Inc. today reported additional clinical ... of CERE-120 in 58 patients with advanced Parkinson,s ... deliver the neurotrophic factor, neurturin, to Parkinson,s disease ...
... Practical Insights on Physician Engagement, Career SuccessSCOTTSDALE, Ariz., ... Corporation, whose Fusionfx solution suite aggregates ... single, clinically relevant views of patient information, today ... papers documenting the increasing involvement of healthcare chief ...
Cached Medicine News:Health News:Gyminee Raises 525K and Relaunches as DailyBurn 2Health News:Entrepreneur Magazine Names American TeleCare, Inc. (ATI) One of the Nation's 100 Brilliant Companies to Watch in 10 Hot Industries 2Health News:Entrepreneur Magazine Names American TeleCare, Inc. (ATI) One of the Nation's 100 Brilliant Companies to Watch in 10 Hot Industries 3Health News:Where Do Americans Spend More Than a Week Each Year? Not on Vacation... 2Health News:Where Do Americans Spend More Than a Week Each Year? Not on Vacation... 3Health News:Where Do Americans Spend More Than a Week Each Year? Not on Vacation... 4Health News:Where Do Americans Spend More Than a Week Each Year? Not on Vacation... 5Health News:Key Stakeholders Convene Capitol Hill Symposium To Advance Convergence of Behavioral Economics and Healthcare 2Health News:Key Stakeholders Convene Capitol Hill Symposium To Advance Convergence of Behavioral Economics and Healthcare 3Health News:Key Stakeholders Convene Capitol Hill Symposium To Advance Convergence of Behavioral Economics and Healthcare 4Health News:Key Stakeholders Convene Capitol Hill Symposium To Advance Convergence of Behavioral Economics and Healthcare 5Health News:Ceregene Presents Additional Clinical Data from Phase 2 Trial of CERE-120 for Parkinson's Disease 2Health News:Ceregene Presents Additional Clinical Data from Phase 2 Trial of CERE-120 for Parkinson's Disease 3Health News:Ceregene Presents Additional Clinical Data from Phase 2 Trial of CERE-120 for Parkinson's Disease 4Health News:Ceregene Presents Additional Clinical Data from Phase 2 Trial of CERE-120 for Parkinson's Disease 5Health News:Carefx's Newest White Paper Illuminates Healthcare CIOs' Growing Role in Operations, Strategic Thinking and IT Project Decision Making 2Health News:Carefx's Newest White Paper Illuminates Healthcare CIOs' Growing Role in Operations, Strategic Thinking and IT Project Decision Making 3
Open 14 mm blades with 10 mm lifting wings. Lightweight wire. Dull finish....
Adjustable lid speculum with mm blades. Miniature frame ideal for deep set eyes and small orbital structures....
Solid 8 mm blades. Dull finish. Most popular size or model....
Solid 6 mm solid blade speculum for newborn or pediatric use....
Medicine Products: